What Researchers Did
Researchers prospectively investigated the efficacy of hyperbaric oxygen therapy combined with intravenous edaravone administration in patients with acute embolic stroke, comparing it to conventional treatment.
What They Found
At 90 days, 6 out of 19 patients (31.6%) in the hyperbaric oxygen and edaravone group achieved a favorable outcome, compared to only 1 out of 19 patients (5.3%) in the control group (p < 0.05). However, there was no significant difference in National Institutes of Health Stroke Scale scores between the two groups at 7 days.
What This Means for Canadian Patients
This pilot study suggests that combining hyperbaric oxygen therapy with edaravone might improve long-term outcomes for Canadian patients experiencing acute embolic stroke. However, these findings require confirmation in larger trials before this treatment can be widely adopted in clinical practice.
Canadian Relevance
This study was conducted in Japan and has no direct Canadian connection.
Study Limitations
Key limitations include the small sample size of this pilot study and its single-center design.